Sei Investments Co. Buys 8,924 Shares of Danaher Corporation (NYSE:DHR)

Sei Investments Co. raised its holdings in Danaher Corporation (NYSE:DHR) by 0.9% during the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 1,026,281 shares of the conglomerate’s stock after purchasing an additional 8,924 shares during the quarter. Danaher accounts for about 2.2% of Sei Investments Co.’s holdings, making the stock its 6th biggest position. Sei Investments Co. owned approximately 0.14% of Danaher worth $233,655,000 at the end of the most recent quarter.

A number of other institutional investors also recently added to or reduced their stakes in DHR. GHP Investment Advisors Inc. lifted its stake in Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after buying an additional 99 shares in the last quarter. Heck Capital Advisors LLC purchased a new stake in Danaher in the 4th quarter valued at approximately $27,000. Sierra Ocean LLC lifted its stake in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after buying an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC purchased a new stake in Danaher in the 1st quarter valued at approximately $31,000. Finally, Dunhill Financial LLC lifted its stake in Danaher by 68.4% in the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock valued at $34,000 after buying an additional 67 shares in the last quarter. Hedge funds and other institutional investors own 79.05% of the company’s stock.

Danaher Stock Up 1.7%

Shares of Danaher stock opened at $209.28 on Thursday. The company has a fifty day moving average price of $199.27 and a 200 day moving average price of $200.40. The company has a current ratio of 1.62, a quick ratio of 1.22 and a debt-to-equity ratio of 0.32. Danaher Corporation has a twelve month low of $171.00 and a twelve month high of $279.90. The stock has a market cap of $149.85 billion, a price-to-earnings ratio of 44.53, a price-to-earnings-growth ratio of 2.87 and a beta of 0.73.

Danaher (NYSE:DHR) last posted its quarterly earnings data on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, beating analysts’ consensus estimates of $1.64 by $0.16. The company had revenue of $5.94 billion during the quarter, compared to analysts’ expectations of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. The firm’s revenue for the quarter was up 3.4% on a year-over-year basis. During the same period in the prior year, the company posted $1.72 EPS. Equities research analysts forecast that Danaher Corporation will post 7.63 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on DHR. Deutsche Bank Aktiengesellschaft cut their price target on Danaher from $240.00 to $235.00 in a report on Thursday, June 5th. Wall Street Zen upgraded Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. The Goldman Sachs Group cut their price target on Danaher from $260.00 to $240.00 and set a “neutral” rating for the company in a report on Wednesday, April 23rd. JPMorgan Chase & Co. cut their price target on Danaher from $280.00 to $260.00 and set an “overweight” rating for the company in a report on Tuesday, April 22nd. Finally, Leerink Partners boosted their price target on Danaher from $225.00 to $230.00 and gave the company an “outperform” rating in a report on Wednesday, April 23rd. Three research analysts have rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, Danaher presently has a consensus rating of “Moderate Buy” and an average price target of $247.61.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.